Madrid, Spain-Botulinum-A toxin shows positive results as an alternativetreatment of neurogenic detrusor overactivity when oral therapies or intravesicalanticholinergics fail or are intolerable, according to results of four separatestudies presented at the European Association of Urology 18th congress here.The agent, although FDA-approved for the treatment of skin wrinkles andrelated indications, is not approved for detrusor overactivity but has beenused by some U.S. and European urologists for this indication.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.